Your browser is no longer supported. Please, upgrade your browser.
Settings
SRPT Sarepta Therapeutics, Inc. daily Stock Chart
SRPT [NASD]
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.64 Insider Own7.00% Shs Outstand54.96M Perf Week16.11%
Market Cap2.25B Forward P/E- EPS next Y-1.65 Insider Trans0.00% Shs Float51.07M Perf Month22.14%
Income-123.40M PEG- EPS next Q-0.90 Inst Own75.80% Short Float23.83% Perf Quarter25.78%
Sales21.80M P/S103.19 EPS this Y-5.50% Inst Trans-0.03% Short Ratio6.52 Perf Half Y19.57%
Book/sh7.82 P/B5.23 EPS next Y-153.80% ROA-30.30% Target Price62.47 Perf Year82.24%
Cash/sh7.10 P/C5.76 EPS next 5Y-0.20% ROE-38.10% 52W Range20.30 - 63.73 Perf YTD49.22%
Dividend- P/FCF- EPS past 5Y- ROI-75.60% 52W High-35.78% Beta1.13
Dividend %- Quick Ratio5.70 Sales past 5Y-35.10% Gross Margin98.20% 52W Low101.63% ATR2.03
Employees197 Current Ratio6.10 Sales Q/Q- Oper. Margin- RSI (14)74.90 Volatility5.42% 4.59%
OptionableYes Debt/Eq0.03 EPS Q/Q214.80% Profit Margin- Rel Volume10.66 Prev Close34.08
ShortableYes LT Debt/Eq0.01 EarningsJul 19 AMC Payout- Avg Volume1.86M Price40.93
Recom1.70 SMA2018.75% SMA5023.01% SMA20018.38% Volume19,886,380 Change20.10%
Jul-20-17Reiterated RBC Capital Mkts Outperform $60 → $64
Apr-28-17Reiterated RBC Capital Mkts Outperform $91 → $60
Apr-05-17Upgrade SunTrust Hold → Buy
Mar-02-17Upgrade Leerink Partners Mkt Perform → Outperform
Mar-02-17Initiated Instinet Buy $84
Mar-01-17Reiterated RBC Capital Mkts Outperform $98 → $91
Feb-22-17Reiterated Needham Buy $81 → $78
Jan-04-17Reiterated Morgan Stanley Equal-Weight $53 → $33
Dec-22-16Initiated JP Morgan Overweight $40
Dec-20-16Initiated Goldman Neutral
Dec-16-16Reiterated RBC Capital Mkts Outperform $106 → $98
Dec-14-16Reiterated Jefferies Hold $46 → $32
Oct-28-16Reiterated RBC Capital Mkts Outperform $108 → $106
Oct-27-16Initiated Morgan Stanley Equal-Weight $53
Oct-18-16Initiated Credit Suisse Outperform $68
Oct-10-16Reiterated Wedbush Outperform $66 → $72
Sep-28-16Reiterated RBC Capital Mkts Outperform $83 → $108
Sep-20-16Reiterated Needham Buy $47 → $81
Sep-19-16Upgrade RBC Capital Mkts Sector Perform → Outperform $5 → $83
Sep-19-16Upgrade Jefferies Underperform → Hold
Jul-21-17 12:29AM  Edited Transcript of SRPT earnings conference call or presentation 19-Jul-17 8:30pm GMT Thomson Reuters StreetEvents
Jul-20-17 04:24PM  Why Kinder Morgan, Ambac Financial, and Sarepta Therapeutics Jumped Today Motley Fool +20.10%
04:14PM  This Biotech Just Blew Past Its Buy Point On A $13 Million Sales Beat Investor's Business Daily
01:09PM  Sarepta Therapeutics (SRPT) Stock Surged 24% Today: Here's Why Zacks
11:36AM  Sarepta Therapeutics Inc (SRPT) Soars on Q2 Revenue, Forecast InvestorPlace
11:29AM  Story Stocks from Briefing.com Briefing.com
10:43AM  Sarepta (SRPT) Q2 Loss Narrows, Ups Exondys 51 Sales View Zacks
09:38AM  Biotech Movers: Sarepta, Inovio, Mylan TheStreet.com
09:30AM  Sarepta rockets 20% higher after 'powerhouse' biotech tops revenue expectations CNBC
08:18AM  Sarepta Therapeutics Incs (SRPT) Earnings Trigger Price Target Boost; Shares Soar 18% SmarterAnalyst
07:30AM  Why Sarepta Therapeutics Stock Rose After-Hours Wednesday Motley Fool
07:30AM  Why Sarepta Therapeutics Stock Is Rising Today Motley Fool
Jul-19-17 09:16PM  Sarepta Therapeutics reports 2Q loss Associated Press
05:37PM  Sarepta shoots higher as sales of $300,000-a-year drug exceed expectations MarketWatch
04:56PM  Sarepta & BioMarin Settle Patent Litigation on Exon Skipping Zacks
04:31PM  Sarepta hikes full-year sales estimate for Duchenne drug American City Business Journals
04:22PM  Sarepta Rockets On Consensus-Crushing Sales, Narrowing Losses Investor's Business Daily
04:01PM  Sarepta Therapeutics Announces Second Quarter 2017 Financial Results and Recent Corporate Developments GlobeNewswire
01:45PM  Sarepta skips over a Duchenne patent battle with $35M settlement American City Business Journals
11:00AM  Investor Network: Sarepta Therapeutics, Inc. to Host Earnings Call Accesswire
08:30AM  Sarepta Therapeutics and Clinigen Launch a Managed Access Program to Treat Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping GlobeNewswire
Jul-18-17 04:30PM  Sarepta Therapeutics Secures $100 Million in Debt Financing GlobeNewswire
01:45PM  BioMarin snags cash as Sarepta skips Duchenne patent battle American City Business Journals
01:32PM  Sarepta, BioMarin Fall After Settling Patent Fight Barrons.com
08:30AM  Sarepta Therapeutics and BioMarin Pharmaceutical Inc. Announce Execution of a Global Settlement and a License Agreement Resolving Exon Skipping Patent Litigation GlobeNewswire
Jul-17-17 04:33PM  How These Biotechs Are Dodging Payor Pushback In Muscular Dystrophy Investor's Business Daily
10:55AM  Sarepta Therapeutics: Say Hello To The New CEO Barrons.com
Jul-12-17 09:30AM  The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Alimera Sciences, Enzo Biochem, Sarepta Therapeutics and EXACT Sciences Zacks
07:01AM  Why Sarepta Therapeutics Stock Picked Up Steam in June Motley Fool
Jul-11-17 09:26AM  5 Top Multibagger Biotech Stocks to Buy in the 2nd Half Zacks
Jun-30-17 06:00PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
10:47AM  Sarepta Looks to Focus on Exondys 51 & DMD Pipeline in 2017 Zacks
Jun-29-17 04:21PM  Could This Biotech Be Headed For A Deal After CEO Takes Reins? Investor's Business Daily
01:20PM  A Veteran CEO Might Be Just What Sarepta Therapeutics Needed Benzinga
10:25AM  Sarepta Appoints Ex-Allergan Executive as CEO and President Zacks
10:12AM  Sarepta: A New CEO Goes a Long Way? Barrons.com
Jun-28-17 06:58PM  Sarepta Therapeutics names new CEO MarketWatch
06:37PM  [$$] Sarepta Taps Chase Pharmaceuticals Chief as Next CEO The Wall Street Journal
05:14PM  Sarepta appoints former Allergan executive Douglas Ingram as CEO Reuters
04:01PM  Sarepta Therapeutics Appoints Douglas S. Ingram as President and Chief Executive Officer GlobeNewswire
09:05AM  Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US : June 28, 2017 Capital Cube
08:30AM  Sarepta Therapeutics to Announce Second Quarter 2017 Financial Results and Recent Corporate Developments on July 19, 2017 GlobeNewswire
Jun-27-17 08:30AM  Sarepta Therapeutics Announces Grand Opening of its Research and Manufacturing Center at Andover GlobeNewswire
Jun-21-17 01:30PM  Scott+Scott, Attorneys at Law, LLP Reminds Investors of its Investigation of Sarepta Therapeutics, Inc. Business Wire +5.55%
08:00AM  Biotech Industry Showing Signs of a Revival in 2017: Today's Research on Gilead Sciences and Sarepta Therapeutics Accesswire
07:00AM  Sarepta Therapeutics and Genethon Announce a Gene Therapy Research Collaboration for the Treatment of Duchenne Muscular Dystrophy GlobeNewswire
Jun-19-17 08:24AM  3 Most Wildly Overvalued Stocks in Biotech (At Least on Paper) Motley Fool
Jun-15-17 04:33PM  Sarepta Therapeutics, Inc. Value Analysis (NASDAQ:SRPT) : June 15, 2017 Capital Cube
04:23PM  3 Healthcare Stocks for Ambitious Investors Motley Fool
03:22PM  ETFs with exposure to Sarepta Therapeutics, Inc. : June 15, 2017 Capital Cube
Jun-14-17 08:20AM  Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : SRPT-US : June 14, 2017 Capital Cube
Jun-08-17 10:06AM  Sarepta: Cheap For an Acquirer? Barrons.com
Jun-07-17 12:21PM  Why Sarepta Therapeutics Stock Imploded in May Motley Fool
Jun-06-17 06:48PM  Cramer's lightning round: You're playing with fire with this heavily shorted stock CNBC
May-31-17 06:30PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
May-30-17 08:30AM  Sarepta Therapeutics to Present Company Overview at the Goldman Sachs 38th Annual Global Healthcare Conference GlobeNewswire
May-26-17 08:28AM  Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : SRPT-US : May 26, 2017 Capital Cube
May-25-17 08:00PM  Reporter sues FDA for documents related to Sarepta drug approval American City Business Journals -5.05%
May-24-17 04:03PM  Sarepta's Most Famous Drugs and Medications Investopedia
07:00AM  What do expensive drugs have in common? A new study breaks it down. American City Business Journals
May-22-17 04:55PM  Why Zoe's Kitchen, GOL, and Sarepta Therapeutics Slumped Today Motley Fool -5.66%
May-20-17 01:32PM  Top hedge fund managers shared these 5 trade ideas at the SALT Conference Yahoo Finance
May-18-17 04:52PM  SALT Spotlight: Why Sarepta is a Buy Barrons.com
03:04PM  Big Fund Managers Offer Up Stock Pick Ideas TheStreet.com
02:44PM  Tourbillon's Karp says Sarepta shares could surge 200 pct Reuters
11:30AM  How the FDA Approved a $300,000-a-Year Drug Its Own Experts Didn't Believe Worked The Wall Street Journal
11:15AM  Former Sarepta CEO launches biotech accelerator with $25M backing American City Business Journals
May-14-17 08:00PM  Henri Termeer, 'giant of biotech' and longtime CEO of Genzyme, dies at 71 American City Business Journals
May-06-17 01:24PM  Should You Buy Into the Hype Surrounding These Stocks? Motley Fool
06:47AM  Sarepta Therapeutics Inc. Stock Rose 22.5% in April. Here's Why. Motley Fool
May-03-17 08:05AM  Edited Transcript of SRPT earnings conference call or presentation 27-Apr-17 8:30pm GMT Thomson Reuters StreetEvents
May-01-17 05:30PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
12:57PM  How Much Would Sarepta Therapeutics Fetch in a Buyout? Motley Fool
11:44AM  Sarepta: Forget a Takeover. This is Why Its CEO's Departure Could Be Good News Barrons.com
07:30AM  Today's Research Reports on Trending Tickers: Sanofi and Sarepta Therapeutics Accesswire
Apr-28-17 04:37PM  Sarepta Pops On Consensus-Topping Revenue, Boosts 2017 Guide Investor's Business Daily
01:37PM  Sarepta Tests Biotech's CEO Vacuum Hypothesis Bloomberg
11:00AM  Sarepta shares jump as CEOs planned exit spurs takeover speculation American City Business Journals
10:43AM  Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Pick Up Zacks
10:16AM  Yes, Sarepta Reported EarningsBut That's Not Why It's Flying Today Barrons.com
09:39AM  Biotech Movers: CEO Exit, Tea Leaf Reading Prompts Surge in Sarepta Shares TheStreet.com
08:34AM  Sarepta CEO Exits Along With a Sanofi Director, So Let's Speculate About a Possible Deal TheStreet.com
Apr-27-17 05:06PM  Sarepta Therapeutics tops Street 1Q forecasts Associated Press
04:01PM  Sarepta Therapeutics Announces First Quarter 2017 Financial Results and Recent Corporate Developments GlobeNewswire
02:00PM  Investor Network: Sarepta Therapeutics, Inc. to Host Earnings Call Accesswire
Apr-26-17 11:43AM  Sarepta: A Victim of High Expectations? Barrons.com
Apr-25-17 08:42AM  Is the Options Market Predicting a Spike in Sarepta (SRPT) Stock? Zacks +5.26%
Apr-24-17 12:17PM  5 Earnings Short-Squeeze Plays: Twitter, Sarepta Therapeutics Included TheStreet.com
11:03AM  Sarepta Pops on Bullish Sentiment Around Duchenne Therapy, PDL Up on Merck Deal: Biotech Movers TheStreet.com
Apr-23-17 01:11PM  Barron's Picks And Pans: Bank Stocks, O'Reilly Automotive, Sarepta And More Benzinga
Apr-22-17 12:50AM  [$$] Drugmaker Sarepta's Stock Could Double Barrons.com
Apr-19-17 03:18PM  Sarepta Therapeutics, Inc. Value Analysis (NASDAQ:SRPT) : April 19, 2017 Capital Cube
Apr-18-17 11:20AM  Scott+Scott, Attorneys at Law, LLP Reminds Investors of its Investigation of Sarepta Therapeutics, Inc. (SRPT) PR Newswire
08:32AM  Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : SRPT-US : April 18, 2017 Capital Cube
07:30AM  FDA Drug Approvals on the Rise in 2017: Today's Research Reports on Sarepta Therapeutics and TG Therapeutics Accesswire
Apr-17-17 08:30AM  Sarepta Therapeutics to Announce First Quarter 2017 Financial Results and Recent Corporate Developments on April 27, 2017 GlobeNewswire
Apr-13-17 12:21PM  Shark Bites: You Don't Want to Play the Gambler Today TheStreet.com
Apr-12-17 04:42PM  Sarepta Therapeutics Stock History: A Biotech Roller-Coaster Ride Motley Fool
Apr-06-17 07:30AM  Today's Research Reports on Biotech Stocks to Watch: Sarepta Therapeutics and Novavax Accesswire
Apr-05-17 05:00PM  Sarepta Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD. The company has a strategic alliance with Nationwide Children's Hospital for the advancement of microdystrophin gene therapy program under the research and option agreement, as well as Galgt2 gene therapy program under the license agreement; Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD under the research collaboration agreement; and Charley's Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies under the research agreement. It also has a license agreement with the University of Western Australia for treatment of DMD by inducing the skipping of certain exons; collaboration and license agreement with Summit (Oxford) Ltd. for the development of ezutromid, an utrophin modulator which is in phase II clinical trials for the treatment of DMD; and a gene therapy research collaboration with Genethon to develop treatments for Duchenne muscular dystrophy. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kaye Edward M. MDPresident, CEO & CMONov 09Option Exercise8.283,00024,84075,635Nov 10 08:19 AM
Howton David TSVP, General CounselNov 09Option Exercise23.851,00023,85022,453Nov 10 08:27 AM
Mahatme SandeshSenior Vice President, CFONov 09Option Exercise23.851,00023,85032,532Nov 10 08:26 AM
Ruff ShamimSVP, Regulatory Affairs & QualNov 08Option Exercise26.241,00026,24021,239Nov 10 08:20 AM
Mahatme SandeshSenior Vice President, CFOOct 17Option Exercise13.9030,000417,00061,532Oct 19 04:22 PM
Mahatme SandeshSenior Vice President, CFOOct 17Sale50.0830,0001,502,50231,532Oct 19 04:22 PM
Ruff ShamimSVP, Regulatory Affairs & QualSep 22Option Exercise13.907,311101,62327,550Sep 30 09:58 PM
Kaye Edward M. MDPresident, CEO & CMOSep 22Option Exercise8.2840,179332,682117,162Sep 26 04:23 PM
Howton David TSVP, General CounselSep 22Option Exercise13.907,00097,30028,453Sep 26 04:19 PM
Ruff ShamimSVP, Regulatory Affairs & QualSep 22Sale60.007,311438,66020,239Sep 30 09:58 PM
Kaye Edward M. MDPresident, CEO & CMOSep 22Sale60.0040,1792,410,74076,983Sep 26 04:23 PM
Howton David TSVP, General CounselSep 22Sale60.007,000420,00021,453Sep 26 04:19 PM
Howton David TSVP, General CounselSep 19Option Exercise13.908,000111,20011,168Sep 21 09:28 PM
Kaye Edward M. MDPresident, CEO & CMOSep 19Option Exercise6.9424,352168,94189,983Sep 21 09:29 PM
Aphale JayantVP, Technical OperationsSep 19Option Exercise4.6235,000161,70036,490Sep 21 09:31 PM
Aphale JayantVP, Technical OperationsSep 19Sale50.0035,0001,750,00011,490Sep 21 09:31 PM
Kaye Edward M. MDPresident, CEO & CMOSep 19Sale50.0024,3521,217,60076,983Sep 21 09:29 PM
Howton David TSVP, General CounselSep 19Sale50.009,304465,2003,168Sep 21 09:28 PM
Kaye Edward M. MDSVP Interim CEO & CMOSep 14Sale30.0024,557736,71076,983Sep 16 04:04 PM